The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
April 15, 2018
The Quarterly Performance Report for the first quarter of the 2017-2018 fiscal year is now available online. Continue reading
March 30, 2018
Click here for more information on authorization for pharmacists to administer meningococcal and shingles vaccines under certain circumstances. Continue reading